Navigation Links
Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development

http://www.reportlinker.com/p0487115/Case-Study-Personalized-Cancer-Therapy---The-era-of-biomarker-identification-and-companion-diagnostic-co-development.html

Introduction

The treatment of cancer has seen a dramatic shift with the addition of molecular targeted therapies. The mixed and unpredictable responses to these targeted therapies are driving the pharmaceutical industry to search for disease and patient characteristics which confer the best response rates. Identification of biomarkers and companion diagnostics will pave the way for personalized cancer therapy.

Scope of this research

• In-depth analysis of companion diagnostic development – when to start development, internal or partnership development, with case study examples

• In-depth analysis of personalized cancer therapy commercial potential – with patient population analysis and case studies

• In-depth analysis of US, EU, and Japanese current and developing regulatory processes for personalized cancer therapy

• Sales forecasts for two key personalized therapies in late stage development - 2010 to 2019 across the seven major markets

Research and analysis Highlights

Pharmaceutical companies face a number of important decisions regarding personalized therapy development. Selecting the correct time to begin companion diagnostic development will help improve the chances of approval and drive new drug uptake. Developers must also assess their position in the market before choosing internal or external development.

Drug developers are cautious of personalized therapies due to the small patient populations and associated commercial potential. However, Herceptin has been able to dominate a well defined segment of the breast cancer market and companion diagnostics have recovered the commercial potential of Erbitux and Vectibix.

Regulators have now realized that the regulatory framework must be altered to incorporate both drugs and companion diagnostics. The US, EU and Japanese authorities are all starting to change their guidelines to encourage personalized therapy development. However, there are still hurdles to overcome before co-development becomes common practice.

Key

Reasons to Purchase this research

• Identify key decisions when developing a drug and companion diagnostic, including internal or external development and when to start development

• Identify the commercial benefits of personalized cancer therapy by assessing drugs currently in development or approved

• Assess the changes in regulatory processes in the seven major markets as the paradigm of personalized cancer medicine grows

TABLE OF CONTENTS

Overview 1

Catalyst 1

Summary 1

About Datamonitor Healthcare 2

About the oncology pharmaceutical analysis team 2

Executive Summary 3

Strategic scoping and focus 3

Datamonitor key findings 3

Related reports 4

Case Study in Personalized Cancer Therapy 6

Introduction 6

Biomarkers 7

Drug and companion diagnostic development 12

Commercial potential 18

Regulators 22

Key pipeline personalized cancer therapies 28

Bibliography 35

Introduction 35

Biomarkers 36

Drug and companion diagnostic development 36

Commercial potential 39

Regulators 41

Key pipeline personalized cancer therapies 42

Appendix A 44

Forecasting assumptions 44

Appendix B 45

Report methodology 45

About Datamonitor 45

To order this report:

: Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type ... tremendous growth is accounted to two main factors. The first is the amazing ... of vendors supplying FireflySci products all around the world. , 2016 was a tremendous ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
Breaking Biology Technology:
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
(Date:1/12/2017)... Oregon and PUNE, India , January 12, 2017 /PRNewswire/ ... Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market ... of 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):